WHAT IS INTERCEPT-MDS?
INTERCEPT-MDS is an Innovative Training Network funded by the European Union’s Horizon 2020 research and innovation programme.
Born from the LifeTime Initiative, the aim of INTERCEPT-MDS is to train Europe’s first experts at the doctorate level in the novel field of disease interception: treating a disease before it fully develops by removing altered cells.
INTERCEPT-MDS brings together 10 European public and private institutions in a European network of experts in leukaemia, epigenetics and single-cell genomics.
Through a multidisciplinary and multisectoral approach, INTERCEPT-MDS will study disease interception in the context of clonal myeloid diseases, using single-cell genomic methods to identify altered cells and test epigenetic perturbations to specifically remove them.
NEWS
1.03.2023
We start March featuring our third ESR of the month: Ângela Mesquita!
Ângela works in Emmet McCormack‘s lab at the University of Bergen developing a new model for myelodysplastic syndromes (MDS) to advance the research of this disease.
To learn more about Ângela and her project, watch her video below and check out the 5Ws of her research here!